Mylan Says Teva's MS Drug IP Suit Doomed By Safe Harbor

Law360, New York (March 11, 2013, 1:55 PM EDT) -- Mylan Inc. on Friday asked a New York federal judge to toss a patent infringement suit over Teva Pharmaceutical Industries Ltd.’s Copaxone, saying it was permitted under a federal safe harbor to use proprietary processes when developing a generic version of the multiple sclerosis drug.

In its motion to dismiss, Mylan cited a provision of federal law that allows use of patented data if the purpose is solely to create a generic drug.

“Any alleged use of the patented markers in connection with the preparation of the...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.